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Introduction {#ehf212657-sec-0004}
============

Heart failure with reduced ejection fraction (HFrEF) is a worldwide problem affecting 1--2% of the total population.[1](#ehf212657-bib-0001){ref-type="ref"} HFrEF is characterized by breathlessness, swelling, and exercise intolerance.[1](#ehf212657-bib-0001){ref-type="ref"} Moreover, comorbidities such as anaemia, diabetes, and sarcopenia/cachexia syndrome might be associated with HFrEF.[2](#ehf212657-bib-0002){ref-type="ref"} In fact, sarcopenia, which is a process of skeletal muscle loss with no change (or even an increase) in fat mass,[3](#ehf212657-bib-0003){ref-type="ref"} is associated with poor outcome and affects around 20% of patients with HFrEF and preserved ejection fraction (HFpEF).[4](#ehf212657-bib-0004){ref-type="ref"} However, little is known about regional fat distribution and its consequence in patients with HFrEF.

Obesity is associated with several metabolic and cardiovascular diseases, including the development of heart failure.[5](#ehf212657-bib-0005){ref-type="ref"} Curiously, overweight/obesity may have a protective role in patients with HFrEF, a phenomenon known as obesity paradox.[6](#ehf212657-bib-0006){ref-type="ref"} However, some patients can also present sarcopenic obesity with similar exercise intolerance as lean patients with muscle wasting.[6](#ehf212657-bib-0006){ref-type="ref"} Recently, it was shown that older, obese patients with HFpEF have larger composition of abdominal fat than healthy controls.[7](#ehf212657-bib-0007){ref-type="ref"} Interestingly, this abdominal fat deposition was associated with lower relative peak oxygen consumption (peak VO~2~) after adjusting for cofactors such as age and sex. However, the impact of body fat distribution, mainly the central adiposity on exercise intolerance in HFrEF is unknown.

For instance, in the general population visceral adiposity is linked to the progression of sarcopenia, inflammation, and insulin resistance.[3](#ehf212657-bib-0003){ref-type="ref"} Moreover, in patients with type 2 diabetes, visceral fat is an independent risk factor for cardiovascular disease.[8](#ehf212657-bib-0008){ref-type="ref"} Fukuda and collaborators found that android to gynoid fat ratio (A/G ratio) was a good predictor of cardiovascular risk in patients with type 2 diabetes.[8](#ehf212657-bib-0008){ref-type="ref"}

Excess of adipose tissue, which contains the enzyme aromatase, metabolizes testosterone to oestrogen with consequent reduction of testosterone concentrations.[9](#ehf212657-bib-0009){ref-type="ref"} These anabolic hormone alterations could also be responsible by the reduction of exercise capacity in patients with HFrEF.[10](#ehf212657-bib-0010){ref-type="ref"} However, these important factors together (adipose distribution, anabolic hormones, and body composition) on exercise tolerance have never been studied in patients with HFrEF.

The aim of this study was to investigate the impact of A/G ratio on functional capacity (peak oxygen consumption) in patients with HFrEF. In addition, we tested the relationship between A/G ratio and anabolic parameters such testosterone, insulin‐like growth factor‐1 (IGF‐1), and dehydroepiandrosterone (DHEA).

Methods {#ehf212657-sec-0005}
=======

Study population {#ehf212657-sec-0006}
----------------

This is a unicentric, cross‐sectional study, where we recruited 118 ambulatory male patients with clinically stable HFrEF. All subjects provided written informed consent at enrolment, and the local ethics committee approved the protocol. Part of the participants of this study is registered at Clinical Trials (NCT01852994 and NCT03190304).

Inclusion criteria were as follows: patients with HFrEF older than 18 years old; history of HFrEF greater than 6 months before the study; signs and symptoms suggestive of HF along with a clinical diagnosis; ischemic and non‐ischemic aetiology; left ventricular ejection fraction (LVEF) \<40%; New York Heart Association functional Class I--III; and compensated HFrEF with optimal medication.

Patients with previous hormonal treatment (testosterone replacement), heart transplantation, a history of unstable angina, myocardial infarction, stroke, cardiovascular revascularization within 6 weeks, biventricular pacemaker with or without implantable cardioverter‐defibrillator, severe kidney dysfunction (under haemodialysis), and liver disease were excluded.

Maximal cardiopulmonary exercise test {#ehf212657-sec-0007}
=====================================

The maximal cardiopulmonary test (Vmax, Mod. 29 S serie YL012278C, Sensor Medics Corporation) was performed on a cycloergometer (Medifit 400L, Medical Fitness Equipment) using a ramp protocol with workload (5 or 10 W) increment every minute. The patients were instructed to pedal at 60 rpm, and workload was increased progressively. The completion of the test occurred when, despite verbal encouragement, the patient could no longer maintain the exercise intensity and the maximal respiratory exchange ratio reached greater than 1.10.[11](#ehf212657-bib-0011){ref-type="ref"} Heart rate was continuously recorded at rest and during the graded exercise testing using a 12‐lead digital electrocardiogram (ERGO PC 13, MICROMED Biotechnology Ltda).

Body composition {#ehf212657-sec-0008}
================

A dual X‐ray absorptiometry (DXA) was used (Lunar iDXA, GE Medical Systems Lunar, Madison, USA) to measure body composition. Dual energy X‐ray absorptiometry measures total mass, fat mass, and fat‐free mass (estimate of muscle mass). Android and gynoid fat were measured, and the ratio between them was calculated (A/G ratio).

Appendicular lean mass (in kilograms) was calculated as the lean muscle mass of both arms and legs divided by the height (in metre) squared. Sarcopenic obesity was defined according to FNIH criteria (appendicular lean mass adjusted for body mass index \< 0.789 for men),[12](#ehf212657-bib-0012){ref-type="ref"} and only those patients with body mass index (BMI) higher than 25 kg/m^2^ were considered either overweight (25.0 to 29.9 kg/m^2^) or obese (30 kg/m^2^ or higher). Patients with BMI lower than 25 kg/m^2^ and with index \<0.789 were not considered sarcopenic. Muscle strength was assessed using the handgrip dynamometer (cutoff point for sarcopenia was defined as proposed by European Working Group on Sarcopenia in Older People).[13](#ehf212657-bib-0013){ref-type="ref"}

Left ventricular ejection fraction evaluation {#ehf212657-sec-0009}
=============================================

Left ventricular ejection fraction was evaluated (Teicholz) using two‐dimensional imaging according to standard methods.[14](#ehf212657-bib-0014){ref-type="ref"}

Blood test {#ehf212657-sec-0010}
==========

All patients had blood drawn in the morning (7:00--11:00 a.m.). Sodium, potassium, creatinine, total cholesterol, high density cholesterol, low density cholesterol, glycaemia, thyroid stimulating hormone, and haemoglobin were measured. In addition, total testosterone, free testosterone, DHEA, and IGF‐1 were measured in all patients. In our local laboratory, serum level of total testosterone (intra‐assay coefficient of variation, ≤7.5%; interassay coefficient of variation, ≤5.4%) and sex hormone‐binding globulin level (normal range, 12--75 nmol/L; intra‐assay coefficient of variation, ≤2.3%; interassay coefficient of variation, ≤6%) were determined using standard laboratory techniques. Total testosterone and sex hormone‐binding globulin levels were used to estimate free testosterone level by using the validated formula.[15](#ehf212657-bib-0015){ref-type="ref"}

Statistics analysis {#ehf212657-sec-0011}
===================

Data are presented as mean ± standard deviation or median and interquartile range (25--75%). The Shapiro--Wilk test was used to assess normality of distribution and Levene\'s test to assess homogeneity. Paired Student\'s *t*‐test or Mann--Whitney test were used to assess the within group differences. Pearson\'s chi‐square test and logistic regression were used as appropriate. The Hosmer and Lemeshow test was used to evaluate the goodness of fit of logistic regression models. A two‐tailed *P* value \< 0.05 indicates statistical significance. For statistical analysis, the Statistical Package for the Social Sciences Version 23 was used.

Results {#ehf212657-sec-0012}
=======

We enrolled 118 male patients with HFrEF, 15 (12.7%) of whom showed sarcopenic obesity. These patients with sarcopenic obesity showed lower functional capacity as measured by peak VO~2~ when compared with non‐sarcopenic patients (1.26 ± 0.35 vs. 1.50 ± 0.47 L/min, *P* = 0.026 and 18.3 ± 5.3 vs. 21.2 ± 6.1 mL/kg/min, *P* = 0.047). In our cohort, the median A/G ratio was 0.55. A/G ratio \>0.55 was detected in 60 patients, while 58 patients presented A/G ratio \<0.55 (*Table* [1](#ehf212657-tbl-0001){ref-type="table"}). The average age of all patients was 56 ± 7 years, and the mean LVEF was 28 ± 7%. Baseline characteristics of patients are summarized in *Table* [1](#ehf212657-tbl-0001){ref-type="table"}. Diuretics and statin were more used in patients with A/G ratio \>0.55, while no differences were observed for other medications between patients with A/G ratio lower or higher than 0.55 (*Table* [1](#ehf212657-tbl-0001){ref-type="table"}).

###### 

Baseline characteristics

  Variable                            All patients (*n* = 118)   A/G \< 0.55 (*n* = 58)   A/G \> 0.55 (*n* = 60)                     *P*‐value
  ---------------------------------- -------------------------- ------------------------ ------------------------ -----------------------------------------------
  Age (years)                                  56 ± 7                    55 ± 8                   57 ± 6                               0.115
  Weight (kg)                              70.89 ± 11.52             65.90 ± 10.24            75.70 ± 10.68                           \<0.001
  BMI (kg/m^2^)                             25.51 ± 3.67              23.48 ± 3.15             27.48 ± 3.03                           \<0.001
  LVEF (%)                                     28 ± 7                    29 ± 7                   28 ± 7                               0.707
  SBP (mmHg)                                102.8 ± 17.6              102.6 ± 13.7             102.9 ± 21.4                            0.917
  DBP (mmHg)                                67.8 ± 10.9               67.7 ± 11.0              67.8 ± 10.7                             0.951
  Ischemic/no ischemic (%)                     24/75                     31/55                    69/44                                0.032
  NYHA‐class I/II/III/IV (%)                 40/39/19/2                51/40/7/2                28/40/30/2                             0.009
  Sodium (mmol/L)                             139 ± 2                   140 ± 3                  140 ± 2                               0.707
  Potassium (mmol/L)                         4.5 ± 0.5                 4.6 ± 0.3                4.5 ± 0.6                              0.307
  Creatinine (mg/dL)                         1.2 ± 0.5                 1.1 ± 0.2                1.3 ± 0.7                             \<0.001
  eGFR (mL/min/1.73m^2^)                      70 ± 20                   74 ± 18                  67 ± 22                               0.063
  Total cholesterol (mmol/L)                  174 ± 43                  180 ± 37                 168 ± 47                              0.119
  HDL (mg/dL)                                 47 ± 16                   53 ± 19                  42 ± 11                              \<0.001
  LDL (mg/dL)                                 104 ± 36                  107 ± 31                 101 ± 41                              0.374
  hs‐CRP (mg/L)                          2.27 (3.86--7.16)         1.71 (1.02--2.38)        3.17 (2.03--4.99)      0.010[a](#ehf212657-note-0002){ref-type="fn"}
  TSH (μIU/mL)                              3.53 ± 4.97               3.15 ± 2.85              3.89 ± 6.39                             0.422
  Haemoglobin (g/dL)                         14.0 ± 1.6                14.1 ± 1.3               14.0 ± 1.8                             0.756
  IGF‐1 (ng/mL)                               152 ± 57                  155 ± 57                 148 ± 58                              0.503
  Peak VO~2~/lean mass (mL/kg/min)           29.1 ± 9.6                30.5 ± 9.1              27.8 ± 10.1                             0.125
  Medications                                                                                                     
  Beta blocker (%)                              100                       100                      100                                 1.000
  ACEi/ARB (%)                                  92.4                      47.5                     44.9                                0.163
  Loop diuretics (%)                            76.3                      31.4                     44.9                                0.002
  Statins (%)                                   58.5                      21.2                     37.3                                0.001
  Spironolactone (%)                            77.1                      37.3                     39.8                                0.828
  Aspirin (%)                                   38.1                      16.9                     21.2                                0.453

A/G, android/gynoid ratio; ACEi/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FT, free testosterone; HDL, high density lipoprotein; hs‐PCR, high sensitivity C‐reactive protein; LVEF, left ventricular ejection fraction; SBP, systolic blood pressure; NYHA, New York Heart Association; TSH, thyroid‐stimulating hormone; TT, total testosterone; VO~2~, oxygen consumption.

Mann--Whitney test with median and interquartile range.

In our cohort, the median VO~2~ in L/min of all patient was 1.41 ± 0.45 L/min. Absolute peak VO~2~ was similar between patients with A/G ratio lower or higher than 0.55 (1.48 ± 0.40 vs. 1.43 ± 0.40 L/min, *P* = 0.559; *Figure* [1](#ehf212657-fig-0001){ref-type="fig"} *A*), while relative peak VO~2~ was lower in patients with A/G ratio \>0.55 (18.7 ± 5.3 vs. 22.5 ± 6.1 mL/kg/min, *P* \< 0.001; *Figure* [1](#ehf212657-fig-0001){ref-type="fig"} *B*).

![(A) Absolute peak oxygen consumption (VO~2~ in L/min) and (B) relative peak VO~2~ in mL/kg/min in patients with heart failure with reduced ejection fraction with lower or higher A/G ratio.](EHF2-7-1101-g001){#ehf212657-fig-0001}

Fasting glucose was higher in male patients with A/G ratio \> 0.55 when compared with patients with A/G ratio \< 0.55 (*Figure* [2](#ehf212657-fig-0002){ref-type="fig"} *A*). We found that 53 (44.9%) patients had pre‐diabetes (glycaemia between 100--125 mg/dL) and 17 (14.4%) had diabetes (glycaemia \> 126 mg/dL) according to the American Diabetes Association. In the other hand, total testosterone and DHEA were significantly decreased in male patients with A/G ratio \> 0.55 when compared with patients with A/G ratio \< 0.55 (*Figure* [2](#ehf212657-fig-0002){ref-type="fig"} *B,D*). We observed a declining trend in free testosterone in patients with A/G ratio \> 0.55 (*Figure* [2](#ehf212657-fig-0002){ref-type="fig"} *C*).

![(A) Glycaemia, (B) total testosterone, (C) free testosterone, and (D) dehydroepiandrosterone (DHEA) in patients with heart failure with reduced ejection fraction with lower or higher A/G ratio. Dashed lines indicate the cutoff point for normality---(A) Glycaemia: 99 mg/dL, (B) total testosterone: 249 ng/dL, and (C) free testosterone: 131 pmol/L. \* = Mann--Whitney test with median and interquartile range.](EHF2-7-1101-g002){#ehf212657-fig-0002}

Fat mass was higher in arms, legs, trunk, and in the total body in male patients with A/G \> 0.55 when compared with patients with A/G \< 0.55 (*Table* [2](#ehf212657-tbl-0002){ref-type="table"}). Moreover, patients with A/G \> 0.55 have increased adipose visceral tissue (mass and volume) when compared with patients with A/G \< 0.55 (*Table* [2](#ehf212657-tbl-0002){ref-type="table"}). Lean mass in the arms and trunk were similar between patients with lower or higher A/G ratio, while we observed a trend to lower lean mass in the legs (*P* = 0.057) and total lean body mass (*P* = 0.055) in patients with A/G \< 0.55 when compared with patients with A/G \> 0.55 (*Table* [2](#ehf212657-tbl-0002){ref-type="table"}).

###### 

Body composition

  Variable                   All patients (*n* = 118)   A/G \< 0.55 (*n* = 58)   A/G \> 0.55 (*n* = 60)   *P*‐value
  -------------------------- -------------------------- ------------------------ ------------------------ -----------
  Upper body composition                                                                                  
  Arms fat mass (g)          1.94 ± 0.63                1.67 ± 0.54              2.22 ± 0.72              \<0.001
  Arms lean mass (g)         6.00 ± 1.04                5.85 ± 1.07              6.15 ± 1.02              0.116
  Trunk fat mass (g)         11.20 ± 4.26               8.27 ± 3.69              14.13 ± 4.82             \<0.001
  Trunk lean mass (g)        23.55 ± 3.12               23.08 ± 3.13             24.02 ± 3.11             0.104
  Lower body composition                                                                                  
  Legs fat mass (g)          5.39 ± 1.57                4.88 ± 1.56              5.91 ± 1.58              0.001
  Legs lean mass (g)         15.78 ± 2.50               15.34 ± 2.47             16.23 ± 2.54             0.057
  Total body composition                                                                                  
  Total fat body mass (g)    19.45 ± 6.23               15.69 ± 5.66             23.20 ± 6.80             \<0.001
  Total lean body mass (g)   48.64 ± 6.32               47.51 ± 6.45             49.77 ± 6.19             0.055
  Adipose visceral tissue                                                                                 
  AVT mass (g)               1.28 ± 0.65                0.68 ± 0.45              1.88 ± 0.86              \<0.001
  AVT volume (cm^3^)         1.34 ± 0.68                0.68 ± 0.45              1.99 ± 0.91              \<0.001

A/G, android/gynoid ratio; AVT, adipose visceral tissue.

In the logistic regression analysis, in which peak VO~2~ was used as dependent variable, we found that age, BMI, LVEF, A/G ratio \>0.55, presence of sarcopenia, and haemoglobin were associated with peak VO~2~ in L/min (all *P* \< 0.05, *Table* [3](#ehf212657-tbl-0003){ref-type="table"}). In multivariate analysis, age, LVEF, A/G ratio \> 0.55, presence of sarcopenia, and haemoglobin remained independently associated with peak VO~2~ in L/min (*P* \< 0.05, *Table* [3](#ehf212657-tbl-0003){ref-type="table"}). During the construction of logistic regression models (using peak VO~2~ as the dependent variable), we included all variables that had been shown to be significantly different between A/G groups. In the univariate analysis, we tested total testosterone \[(*P* = 0.819, odds ratio (OR) 1.000 (0.998‐1.001)\], statins \[(*P* = 0.434, OR 2.000 (0.352--11.364)\], creatine \[(*P* = 0.195, OR 0.586 (0.261--1.315)\], high density cholesterol‐C \[(*P* = 0.225, OR 1.015 (0.991--1.040)\], glycaemia \[(*P* = 0.662, OR 1.004 (0.987--1.022)\], and diuretic \[(*P* = 0.037, OR 2.598 (1.058--6.382)\]. Only diuretic was correlated in the univariate analysis; however, diuretic did not show statistical significance after adjusting for cofactors such as age, BMI, LVEF, A/G ratio, sarcopenia, and haemoglobin \[(*P* = 0.451, OR 1.654 (0.447--6.114)\].

###### 

Logistic regression model defined as the absolute peak VO~2~ in L/min below the median (1.41 ± 0.45 L/min) serving as the dependent variable

  Variable                            Univariate   Multivariate                                      
  ----------------------------------- ------------ --------------- --------- ------- --------------- -------
  Age (per year increase)             0.913        0.860--0.970    0.003     0.922   0.853--0.996    0.039
  BMI (per kg/m^2^ increase)          1.121        1.009--1.245    0.034     1.036   0.832--1.289    0.754
  LVEF (per 1% decrease)              1.061        1.009--1.115    0.021     1.103   1.032--1.180    0.004
  TT (per 1 ng/dL decrease)           1.000        0.998--1.001    0.819                             
  FT (per 1 mmol/L decrease)          1.002        0.999--1.006    0.819                             
  A/G ratio \> 0.55 (present)         2.094        0.996--4.405    0.050     3.895   1.030--14.730   0.045
  Sarcopenia (present)                7.269        2.693--19.618   \<0.001   8.373   1.743--40.221   0.008
  Haemoglobin (per 1 g/dL decrease)   1.910        1.406--2.596    \<0.001   1.815   1.269--2.598    0.001
  Diabetes \>126 mg/dL (present)      1.168        0.391--3.489    0.781                             

  Absolute peak VO~2~ in mL/kg/min below the median (19.90 ± 6.03 mL/kg/min)                                                         
  ---------------------------------------------------------------------------- ------- -------------- ------- ------- -------------- -------
  Age (per year increase)                                                      0.939   0.888--0.992   0.026   0.945   0.886--1.008   0.012
  BMI (per kg/m2 increase)                                                     0.966   0.873--1.068   0.497                          
  LVEF (per 1% decrease)                                                       1.063   1.011--1.118   0.018   1.084   1.023--1.147   0.006
  TT (per 1 ng/dL decrease)                                                    1.001   1.000--1.003   0.136                          
  FT (per 1 mmol/L decrease)                                                   1.003   0.999--1.007   0.140                          
  A/G ratio \> 0.55 (present)                                                  3.020   1.414--6.453   0.004   3.024   1.276--7.170   0.012
  Sarcopenia (present)                                                         1.649   0.721--3.769   0.236                          
  Haemoglobin (per 1 g/dL decrease)                                            1.575   1.200--2.067   0.001   1.606   1.180--2.185   0.003
  Diabetes \> 126 mg/dL (present)                                              1.637   0.528--5.075   0.393                          

Hosmer and Lemeshow Test, Chi‐squared: 4.427, *df*: 8, *P*‐value = 0.817.

A/G, android/gynoid ratio; BMI, body mass index; CI, confidence interval; LVEF, left ventricular ejection fraction; OR, odds ratio; TT, total testosterone; FT, free testosterone.

In the second logistic regression analysis, we used peak VO~2~ in mL/kg/min as the dependent variable. In the univariable logistic regression, we found that age, LVEF, A/G ratio \> 0.55, and haemoglobin were associated with peak VO~2~ in mL/kg/min (all *P* \< 0.05, *Table* [3](#ehf212657-tbl-0003){ref-type="table"}). In multivariate analysis, age, LVEF, A/G ratio \> 0.55, and haemoglobin remained independently associated with peak VO~2~ in mL/kg/min (*P* \< 0.05, *Table* [3](#ehf212657-tbl-0003){ref-type="table"}).

Discussion {#ehf212657-sec-0013}
==========

This is the first study to show an association between android and gynoid fat on functional capacity in male patients with HFrEF. The main findings were that male patients with higher A/G ratio (\>0.55) have lower peak VO~2~ when adjusted by total weight, but not in absolute value (in L/min). In a logistic regression model adjusted by cofactors, A/G ratio was strong associated with lower VO~2~. In addition, similarly observed in patients with obesity or metabolic syndrome,[16](#ehf212657-bib-0016){ref-type="ref"} those patients with HFrEF and higher central fat deposition have a slightly increase in glycaemia with lower anabolic hormones such as testosterone and DHEA. However, after adjusting for cofactors, anabolic hormones did not correlate with VO~2~.

Comorbidities in patients with HFrEF are prevalent, and it is associated with worse quality of life and poor outcome.[2](#ehf212657-bib-0002){ref-type="ref"}, [4](#ehf212657-bib-0004){ref-type="ref"}, [17](#ehf212657-bib-0017){ref-type="ref"} Sarcopenia in patients with HFrEF has been shown an important marker of mortality, affecting approximately 20% of this population.[18](#ehf212657-bib-0018){ref-type="ref"} Moreover, several patients with HFrEF can also present an overlap in wasting syndromes (cachexia and sarcopenia),[19](#ehf212657-bib-0019){ref-type="ref"} and cachexia is associated with an increased rate of mortality (50% of mortality in 18 months of follow‐up).[17](#ehf212657-bib-0017){ref-type="ref"} Interestingly, obesity may have a protective effect in patients with HFrEF because higher body weight prevents loss of muscle mass.[6](#ehf212657-bib-0006){ref-type="ref"} However, this phenomenon known as obesity paradox should be more explored, because greater abdominal, cardiac, and intermuscular fat are associated with lower physical function in patients with HFpEF.[7](#ehf212657-bib-0007){ref-type="ref"} Moreover, an increased waist‐to‐hip ratio is associated with a higher risk of mortality in female but not in male patients with HFrEF.[20](#ehf212657-bib-0020){ref-type="ref"} For these reasons, regional adipose‐induced exercise intolerance in HFrEF should be more studied. Several studies suggest that the use of VO~2~ adjusted by lean body mass (cutoff \< 19 mL O~2~/kg of lean body mass/min) should be used for timing transplantation, particularly in women and in patients with excess adiposity,[21](#ehf212657-bib-0021){ref-type="ref"}, [22](#ehf212657-bib-0022){ref-type="ref"} because peripheral skeletal muscle dysfunction meaningfully contribute to the development of sarcopenia, sarcopenic obesity, and cachexia.[23](#ehf212657-bib-0023){ref-type="ref"} In our study, we extend this knowledge to the possible role of central fat and its influence on exercise intolerance in patients with HFrEF.

Adipose‐induced inflammation is a hallmark of adverse effects including endothelial dysfunction and impaired skeletal muscle mitochondrial function, with consequent reduction of skeletal muscle oxygen delivery and extraction.[24](#ehf212657-bib-0024){ref-type="ref"}, [25](#ehf212657-bib-0025){ref-type="ref"}, [26](#ehf212657-bib-0026){ref-type="ref"} In an experimental model, accumulation of visceral fat led to generation of reactive oxygen species and markedly lower maximal VO~2~.[27](#ehf212657-bib-0027){ref-type="ref"} In patients with heart failure, exercise training reduced visceral adipose tissue with significant correlation with exercise capacity improvement.[28](#ehf212657-bib-0028){ref-type="ref"}

These findings point out abdominal adipose‐induced exercise intolerance in heart failure, and exercise training, which plays a role on anti‐inflammatory process, increases expression of interleukin‐10 and decreases interleukin‐6.[29](#ehf212657-bib-0029){ref-type="ref"} Furthermore, exercise improves adiponectin and insulin resistance in obese individuals with diabetes, favouring cardiac energy metabolism via AMP‐activated protein kinase.[30](#ehf212657-bib-0030){ref-type="ref"}, [31](#ehf212657-bib-0031){ref-type="ref"} These mechanisms may be involved in the relationship between visceral adipose tissue and exercise capacity in patients HFrEF. However, these mechanisms should be investigated in future studies.

Obesity per se decreases mitochondrial oxidative capacity through reduced expression of electron transport chain components and/or their enzymatic capacity.[32](#ehf212657-bib-0032){ref-type="ref"} Subcutaneous depots obtained from obese patients revealed a reduced membrane potential, inorganic phosphate utilization, and the activities of respiratory chain complexes I--IV in isolated mitochondria from subcutaneous depots.[33](#ehf212657-bib-0033){ref-type="ref"} Taken together, impaired mitochondrial oxidative capacity, mainly in white adipose tissue, and generation of reactive oxygen species might be the mechanisms involved in the blunted energetic production and exercise intolerance in patients with HFrEF.

In conclusion, our data suggest that in addition to well‐known cofactors such as age and the presence of sarcopenia in functional capacity worsening, body fat distribution, particularly android and gynoid fat composition, might have an important adverse role on functional capacity in male patients with HFrEF.

This study has limitations. First, adipose visceral fat was estimated by DXA. Computed tomography (CT) and magnetic resonance imaging are the gold standard method to measure visceral fat. However, DXA has a strong correlation with CT (0.949 for males) to estimate adipose visceral fat[34](#ehf212657-bib-0034){ref-type="ref"} with minimal bias from CT or magnetic resonance imaging.[35](#ehf212657-bib-0035){ref-type="ref"} Second, we studied only male patients with HFrEF. Therefore, our results are restricted to this population.
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